| Texto completo | |
| Autor(es): Mostrar menos - |
Nani, V, Joao
;
Dal Mas, Caroline
[1]
;
Yonamine, Camila M.
[1]
;
Ota, Vanessa K.
[2]
;
Noto, Cristiano
[3, 4]
;
Belangero, I, Sintia
;
Mari, Jair J.
[3]
;
Bressan, Rodrigo
[3]
;
Cordeiro, Quirino
[4]
;
Gadelha, Ary
[3]
;
Hayashi, Mirian A. F.
[1, 5]
Número total de Autores: 11
|
| Afiliação do(s) autor(es): | [1] Nani, Joao, V, Univ Fed Sao Paulo UNIFESP, Dept Pharmacol, Sao Paulo - Brazil
[2] I, Univ Fed Sao Paulo UNIFESP, Dept Genet, Sao Paulo - Brazil
[3] Nani, Joao, V, Univ Fed Sao Paulo UNIFESP, Dept Psychiat, Sao Paulo - Brazil
[4] Univ Fed Sao Paulo UNIFESP, First Episode Psychosis Program, Sao Paulo - Brazil
[5] Nani, Joao, V, CNPq, Natl Inst Translat Med INCT TM, Ribeirao Preto - Brazil
Número total de Afiliações: 5
|
| Tipo de documento: | Artigo Científico |
| Fonte: | INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY; v. 23, n. 11, p. 721-730, NOV 2020. |
| Citações Web of Science: | 0 |
| Resumo | |
Background: Our previous studies showed increased angiotensin I-converting enzyme (ACE) activity in chronic schizophrenia patients compared with healthy control (HC) volunteers, and the relevance of combining ACE genotype and activity for predicting schizophrenia was suggested. Methods: ACE activity was measured in plasma of ACE insertion/deletion (I/D) genotyped HC volunteers (n = 53) and antipsychotic-naive first-episode psychosis (FEP) patients (n = 45) assessed at baseline (FEB-B) and also after 2 months (FEP2M) of treatment with the atypical antipsychotic risperidone. Results: ACE activity measurements showed significant differences among HC, FEP-B, and FEP-2M groups (F = 5.356, df = 2, P =.005) as well as between HC and FEP-2M (post-hoc Tukey's multiple comparisons test, P =.004). No correlation was observed for ACE activity increases and symptom severity reductions in FEP as assessed by total Positive and Negative Syndrome Scale (r = -0.131, P =.434). FEP subgrouped by ACE I/D genotype showed significant ACE activity increases, mainly in the DD genotype subgroup. No correlation between ACE activity and age was observed in FEP or HC groups separately (r = 0.210, P =.392), but ACE activity level differences observed between these groups were influenced by age. Conclusions: The importance of measuring the ACE activity in blood plasma, associated with ACE I/D genotyping to support the follow-up of FEP patients, did not show correlation with general symptom amelioration in the present study. However, new insights into the influence of age and I/D genotype for ACE activity changes in FEP individuals upon treatment was demonstrated. (AU) | |
| Processo FAPESP: | 17/25016-8 - Investigação da resposta ao tratamento da esquizofrenia com risperidona: estudo farmacogenético em uma coorte de pacientes em primeiro episódio psicótico |
| Beneficiário: | Síntia Iole Nogueira Belangero |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 17/02413-1 - Validação da crotamina como biomarcador e avaliação do seu potencial uso na terapia de doenças humanas |
| Beneficiário: | Mirian Akemi Furuie Hayashi |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 12/08941-6 - Estudo das oligopeptidases na esquizofrenia |
| Beneficiário: | Camila Miyagui Yonamine Asanuma |
| Modalidade de apoio: | Bolsas no Brasil - Pós-Doutorado |
| Processo FAPESP: | 19/09207-3 - Estudo do(s) mecanismo(s) molecular(es) e celular(es) em transtornos mentais |
| Beneficiário: | João Victor Silva Nani |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |